Rationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management) : study protocol by Peters-Klimm, Frank et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Study protocol
Rationale, design and conduct of a randomised controlled trial 
evaluating a primary care-based complex intervention to improve 
the quality of life of heart failure patients: HICMan (Heidelberg 
Integrated Case Management)
Frank Peters-Klimm*1, Thomas Müller-Tasch2, Dieter Schellberg2, 
Jochen Gensichen3, Christiane Muth3, Wolfgang Herzog2 and 
Joachim Szecsenyi1
Address: 1Department of General Practice and Health Services Research, University Hospital of Heidelberg, Voßstraße 2, 69115 Heidelberg, 
Germany, 2Department of Psychosomatic and General Internal Medicine, University of Heidelberg Hospital, Germany and 3Institute for General 
Practice, Chronic Care and Health Services Research University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt a. M., Germany
Email: Frank Peters-Klimm* - Frank.Peters@med.uni-heidelberg.de; Thomas Müller-Tasch - Thomas.Mueller-Tasch@med.uni-heidelberg.de; 
Dieter Schellberg - Dieter.Schellberg@med.uni-heidelberg.de; Jochen Gensichen - Gensichen@allgemeinmedizin.uni-frankfurt.de; 
Christiane Muth - Muth@allgemeinmedizin.uni-frankfurt.de; Wolfgang Herzog - Wolfgang.Herzog@med.uni-heidelberg.de; 
Joachim Szecsenyi - Joachim.Szecsenyi@med.uni-heidelberg.de
* Corresponding author    
Abstract
Background: Chronic congestive heart failure (CHF) is a complex disease with rising prevalence,
compromised quality of life (QoL), unplanned hospital admissions, high mortality and therefore high
burden of illness. The delivery of care for these patients has been criticized and new strategies
addressing crucial domains of care have been shown to be effective on patients' health outcomes,
although these trials were conducted in secondary care or in highly organised Health Maintenance
Organisations. It remains unclear whether a comprehensive primary care-based case management
for the treating general practitioner (GP) can improve patients' QoL.
Methods/Design:  HICMan is a randomised controlled trial with patients as the unit of
randomisation. Aim is to evaluate a structured, standardized and comprehensive complex
intervention for patients with CHF in a 12-months follow-up trial.
Patients from intervention group receive specific patient leaflets and documentation booklets as
well as regular monitoring and screening by a prior trained practice nurse, who gives feedback to
the GP upon urgency. Monitoring and screening address aspects of disease-specific self-
management, (non)pharmacological adherence and psychosomatic and geriatric comorbidity. GPs
are invited to provide a tailored structured counselling 4 times during the trial and receive an
additional feedback on pharmacotherapy relevant to prognosis (data of baseline documentation).
Patients from control group receive usual care by their GPs, who were introduced to guideline-
oriented management and a tailored health counselling concept.
Main outcome measurement for patients' QoL is the scale physical functioning of the SF-36 health
questionnaire in a 12-month follow-up. Secondary outcomes are the disease specific QoL
Published: 23 August 2007
BMC Cardiovascular Disorders 2007, 7:25 doi:10.1186/1471-2261-7-25
Received: 28 June 2007
Accepted: 23 August 2007
This article is available from: http://www.biomedcentral.com/1471-2261/7/25
© 2007 Peters-Klimm et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2007, 7:25 http://www.biomedcentral.com/1471-2261/7/25
Page 2 of 8
(page number not for citation purposes)
measured by the Kansas City Cardiomyopathy questionnaire (KCCQ), depression and anxiety
disorders (PHQ-9, GAD-7), adherence (EHFScBS and SANA), quality of care measured by an
adapted version of the Patient Chronic Illness Assessment of Care questionnaire (PACIC) and NT-
proBNP. In addition, comprehensive clinical data are collected about health status, comorbidity,
medication and health care utilisation.
Discussion:  As the targeted patient group is mostly cared for and treated by GPs, a
comprehensive primary care-based guideline implementation including somatic, psychosomatic and
organisational aspects of the delivery of care (HICMAn) is a promising intervention applying proven
strategies for optimal care.
Trial registration: Current Controlled Trials ISRCTN30822978.
Background
Congestive Heart Failure (CHF) is a disease with high inci-
dence, prevalence, and the cumulative lifetime risk to
develop CHF of 20% [1-3]. Despite substantial progress in
medical treatment [4], one-year mortality ranges stage-
dependently from 7 to 28% and increases to 75% after
five years [5,6]. The burden of illness includes multiple
acute failures followed by hospital admissions [7]. New
treatment strategies focus on preventing readmissions and
on improving the prognosis. With a higher stage of CHF
the Quality of life (QoL) decreases [8]. Some studies sug-
gest that QoL is a predictor of the course of CHF, inde-
pendent of the acknowledged somatic predictors of
prognosis (like left ventricular ejection fraction) [8,9].
Improvement of mortality rates by pharmacotherapy does
not necessarily implicate improvement of QoL[10]. Non-
medical treatment like exercise training and patient edu-
cation have been shown to have a high impact on QoL
[11]. However, it has been shown that the known clinical
and somatic predictors explain only about 40% of the
total variance of QoL [8,12].
Transfer of these new insights has not been implemented
in daily practice, although specific care taking psychoso-
cial aspects into account has been demanded [13,14].
However, there are no concepts for specific training deal-
ing with patients with CHF to improve their QoL in Pri-
mary Care. Although QoL is a main concern of patients, it
is not a central topic of cardiac research.
To date, only small-scale studies with selective samples
analysed data regarding QoL in patients with CHF. In
addition, there is no horizontal and vertical networking
for transfer of knowledge. This is especially the case for the
transfer of specific interventions for general practice.
There are several guidelines for the management of
patients with heart failure[15], but adherence to these
guidelines is low [16].
Novel aspect of integrated case management
To our knowledge, the proposed study is the first investi-
gating the efficacy of a multifaceted case management in
patients with CHF in general practice in Germany. Studies
showing the efficacy of case management in patients with
CHF were performed in highly organised Health Mainte-
nance Organisations and have therefore limited external
validity. GPs in Germany as in many other countries work
mostly in single or double practices without multi-profes-
sional teams. A nurse specialist exerting a form of struc-
tured care is new to the German system. The structured
care intervention consists of telephone monitoring, home
visits with additional diagnostic screening, medication
feedback, patient leaflets, and specific counseling allow-
ing assessment of and intervention in a multitude of
aspects of care relevant to the patient. Provided that our
intervention proves to be effective, the better treatment of
patients with CHF in general practice could prevent per-
sonal suffering, improve patient and provider satisfaction,
and lower health care costs.
Evidence
The following studies give evidence for the necessity, clin-
ical relevance, and novelty of the trial: Depressive symp-
toms and quality of life are strongly associated
variables[17]. QoL and depressive disorders are predictive
for unscheduled readmissions and mortality[8,9,18-20].
In the "Improvement of Heart Failure Initiative Study" the
level of knowledge, the diagnostic as well as the therapeu-
tic approach of 100 GPs (900 patients) have been evalu-
ated. As the results show, patients in Germany are treated
according to guidelines only in about 20% of the cases.
Cardiologists and GPs set different priorities concerning
diagnostics and therapy [21,22]. Improvement of mortal-
ity rates by pharmacotherapy does not implicate improve-
ment of QoL[10]. Studies evaluating "complex" case
management for CHF in or starting from secondary care
have shown to have favourable outcome with regard to
QoL, readmission and mortality [23]. Sustained effects
have been shown in long-term follow-ups [24].BMC Cardiovascular Disorders 2007, 7:25 http://www.biomedcentral.com/1471-2261/7/25
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Methods/Design
Aims of the study
With the purpose to improve QoL and physical outcomes
this study aims to investigate multifaceted case manage-
ment of patients with CHF in general practice. Therefore,
an intervention that specifically addresses the needs of
this patient group will be compared to usual treatment as
control condition.
Scientific hypothesis
The case management intervention group shows a signifi-
cantly better outcome with respect to QoL compared to
the control group at the one-year follow-up. We further
expect greater improvements in the intervention subjects
compared to controls with respect to readmission and
mortality, physical outcomes parameters (NYHA and NT-
proBNP), patients' satisfaction with medical care and
health service utilization.
Study/trial design
A (prospective,) two-armed, randomised controlled trial
will be performed, with the patients as unit of randomisa-
tion. This trial design was chosen because of high internal
validity, while the number of needed recruited patients
remains feasible. Contamination is avoided as the inter-
vention is highly standardized, time-consuming and
linked to a personal one-time documentation. Eligible
patients will be randomized to either intervention or
usual care conditions (see figure 1).
Sample size/Power calculations
We expect that the differences in QoL between the inter-
ventional and control arm to be at least 9% with superior
QoL in the interventional arm (physical functioning,
Scale 1 of SF-36). With a serial correlation of 0.6, n = 66
patients are needed per arm for 80% power at an alpha-
level of 5%. Calculating a drop-out of 30%, 132 cases rep-
resent 70%. Therefore, at least 188 patients will be ini-
tially included.
Recruitment of GPs and randomisation
GPs were eligible for randomization if their practice had a
contract with all German insurances, ensuring that
patients of all social levels have unlimited admission to
the practice. About 200 GPs in the area of Baden-Wuert-
temberg, fulfilling the inclusion criteria, were invited by a
formal letter from the Department of General Practice and
Health Services Research of the University Hospital Hei-
delberg, to participate in the study. 36 GPs gave their writ-
ten consent to participate in the study. 5 GPs declined to
participate prior to randomisation, two due to lack of eli-
gible patients, two due to high time and effort and one
because of disagreement concerning the "evidence based"
approach. Based on detailed information about the prac-
tice and the GP, the inclusion criteria were checked. No
GP or no practice had to be excluded due to the inclusion
criteria. Of the participating 31 centres 19 took part in the
previous train the trainer-study (ttt) about guideline
implementation. In this RCT general practitioners (GPs)
of the intervention group got a special training in a clini-
cal practice guideline (CPG) on CHF while GPs of the con-
Trial design (HICMan-CHF) Figure 1
Trial design (HICMan-CHF).BMC Cardiovascular Disorders 2007, 7:25 http://www.biomedcentral.com/1471-2261/7/25
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trol group merely got the CPG with a standard lecture, and
we compared the QoL of CHF patients in both groups.
The participating GPs of the ttt-study were invited to con-
tinue in the HICMan-study.
From November 2006 to January 2007, 31 recruiting cen-
tres (with about 6–7 recruited patients per centre)
enrolled 200 eligible patients and obtained informed con-
sent prior to allocation. We used third party fax randomi-
sation, conducted by the Coordination Centre for Clinical
Trials Leipzig (KKSL). KKSL obtained the randomisation
faxes directly from the centres and conducted the proce-
dure based on a computer generated, concealed random
allocation sequence using an algorithm of Pocock:
Patients were grouped by the interval of recruitment time.
Each group was randomised immediately at the end of the
respective recruitment interval, stratified by arm and cen-
tre. Assignment of the patients to their intervention arm
was sent by fax from KKSL to the centres. The assessors of
outcomes are blinded until post-intervention data collec-
tion is completed.
Inclusion/exclusion criteria
Case manager inclusion criteria
For the practice nurses who wanted to engage in the study,
the following criteria had to be fulfilled apart from the
participation in the study's case management work shops:
status of practice nurse or at least in the third year of for-
mal training.
Patient inclusion criteria
To be eligible for the study, patients had to fulfil the fol-
lowing inclusion criteria: age> = 40 years, objective left
ventricular CHF, ejection fraction of 45% or less (con-
firmed by echocardiography within the last 24 months),
no dyspnea (NYHA I), but hospital admission because of
CHF within the last 24 months or dyspnea NYHA II-IV,
stability of the disease at the time of inclusion, capability
to give informed consent.
Patient exclusion criteria
To be eligible for the study, the following criteria had to
be excluded: participation in another clinical trial or spe-
cific care concept within the last 30 days (incl. telemedi-
cine interventions), residency in a nursing home, primary
valvular heart disease with relevant hemodynamic effects,
Hypertrophic Obstructive/Restrictive Cardiomyopathy
(HOCM/RCM), status post/pre organ transplantation,
acute left ventricular failure, short life expectancy of < 2
years due to serious concomitant illness, known impaired
mental state (e.g. dementia) that prevents accurate
answers to questions, addictive disorders with continuing
drug abuse despite social, legal or professional conflicts.
Data collection
After giving their informed and written consent to partici-
pate in the study, patients were registered in the Centre of
the Competence Network of Heart Failure (Berlin) which
is responsible for administration, coordination and pseu-
donymisation of patients' personal data.
Patients will receive a questionnaire for evaluation of
generic QoL (SF-36) and disease-specific QoL (KCCQ) as
well as other items to assess secondary outcome parame-
ters as shown in table 1. GPs will document clinical data
(history, actual clinical status, lab results, ECG etc.) and
draw a blood sample for determination of NT-pro-BNP.
Analysis of blood samples will be performed by the Char-
ité Universitätsmedizin Berlin. A study nurse will collect
the documents in the practice and forward them to the
Table 1: Outcome-parameter and instruments
Outcome-parameter Instrument
Primary outcome
Quality of life SF-36, scale 1 (PF)
Secondary outcomes
Quality of life other scales of SF-36
Disease-specific Quality of life KCCQ
Depression PHQ-9
Anxiety disorder GAD-7
Patient assessment of care Modified PACIC
Adherence EHFScBS and SANA
Disease course NT-proBNP
Other comorbidity CIRS, small geriatric assessment
Health care utilisation Case report form (CRF)
Medication CRF
Sociodemographic variables Questionnaire
HICMan documentation of CM CRF, PHQ-9, GAD-7 and small geriatric assessmentBMC Cardiovascular Disorders 2007, 7:25 http://www.biomedcentral.com/1471-2261/7/25
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Coordination Centre for Clinical Trials Leipzig (KKSL,
Germany), which is responsible for data management
(database set-up and validation, data entry, coding, query
management and case report form printing).
Outcome-parameter
Primary and secondary outcomes
Table 1 displays the outcome parameters and associated
instruments used. The primary outcome is quality of life
assessed by the Short Form 36 Health Questionnaire
(physical function scale)[25], an internationally validated
generic instrument for the assessment of quality of life.
Secondary outcomes are the other scales of SF-36[25], dis-
ease-specific QoL (KCCQ [26]), signs for depressive and
anxiety disorders (PHQ-9 and GAD-7)[27,28], Patient
Assessment of Chronic Illness Care (modified PACIC
[29]), admission to hospital or death due to heart failure
(combined), improvement of heart failure according to
functional status (NYHA) and NT-proBNP [30], the Euro-
pean Heart Failure Selfcare Behaviour Scale (EHF-
ScBS[31]), the Scales to Assess Low Adherence
(SANA[32]), evidence-based pharmacotherapy and cost-
effectiveness. Additionally, the case management will be
analysed. This includes the used monitoring list and
screening tools (study specific assessment of patients
behaviour regarding life style, PHQ-9, GAD-7 and small
geriatric assessment [33-35]).
These data will be compiled from patient questionnaires
and case report forms of the patients. All instruments
except SANA and PACIC represent well established instru-
ments that are validated in Germany. No interim analysis
will be performed except for pharmacotherapy to provide
prescription feedback.
Intervention/Follow-ups
Patients randomised to the intervention arm will get case
management care by a specifically trained practice nurse
(case manager = CM). Duration of training was 1,5 days.
All patients receive an introduction of the CM, monitor-
ing by telephone, home visits, disease-specific counsel-
ling, and surveillance concerning prescription. Details are
listed below:
1. Introduction: After enrolment, the CM will take approx-
imately 30 min. for introducing her function and estab-
lishing a relationship to the patient. Patients get
information about their disease, realisation of symptoms
and self-monitoring (shortness of breath, fatigue, periph-
eral oedema, weight, heart rate and blood pressure). On
that occasion, patients will get an information booklet
and documentation booklet.
2. Monitoring by telephone: The CM carries out a tele-
phone monitoring according to the patients' risk:
• low to medium risk (NYHA I/II) – every six weeks, three
personal home visits during the year instead of telephone
monitoring.
• high risk (NYHA III/IV) – every three weeks, three per-
sonal home visits during the year instead of telephone
monitoring.
Content of the telephone interview will check for physical
warning physical signs, problems with medication
(adherence).
3. Home visits: During home visits (three times a year)
certain domains from the following will be evaluated in a
structured and operated way tailored to heart failure
patients: Physical, cardiac status; structured assessment of
lifestyle [36] (as first step part of a 5-A counselling, see
below); adherence; depression and anxiety disorder
screening (2×); small geriatric assessment (2×) and a
detailed medication check (1×).
4. After the introduction and the three home visits, the
patients will get a specific physician encounter for coun-
selling as part of a 5-A counselling [37,38] based on the
structured assessment of relevant lifestyle and habits in
relation to heart failure concerning the topics (i) self man-
agement, (ii) physical activity and (iii) smoking.
5. Recall-Reminder-Systems: if necessary, active surveil-
lance concerning prescription or doctor follow-ups will be
applied.
6. In month seven, GPs will receive an additional feedback
on pharmacotherapy relevant to prognosis for patients
from the IG (data of baseline documentation). Substances
from the following classes will be transformed from the
following three drug classes: ACE-inhibitors (or angi-
otensin-II receptor antagonists), beta-blockers and aldos-
terone antagonists. Percentage of reached target dose
(from current guideline) will be calculated. The procedure
will be performed by a statistician not involved in the con-
duct of the study. GPs will get a printout showing a graph-
ical depiction of each patient from the IG (he is caring
for).
Actions to take by the CM
During each visit, the CM will apply a structured and for-
malised assessment of cardiac/physical functioning and
additional screening according to the structured plan, as
outlined above. Results of the screening will guide the CM
to tangible actions, which consist of a feedback or, if nec-BMC Cardiovascular Disorders 2007, 7:25 http://www.biomedcentral.com/1471-2261/7/25
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essary, of direct contact to/with the treating physician
upon urgency.
Control condition
Participating physicians will receive a guideline for the
management of heart failure as the recommended stand-
ard and the introduction to a structured counselling for
heart failure (5-A). No case management will be applied
to the patients of this group.
Follow-ups
CM home visits will take place at the beginning, after the
first and the second third of the year. Assessment and doc-
umentation will take place at the beginning and the end
of the year (see figure 1).
Timeframe of the study
The study has the following phases: Training of study
nurse and preparation of trial (months 1 – 6), recruitment
(months 1 – 6), treatment/control (months 7 – 18), fol-
low-up (month 18), data entry (months 19–20), data
analyses and publication of results (months 21–24). At
the time of drafting the manuscript, the planned time
schedule is kept: 200 patients were enrolled. The study
was in the phase of treatment/control in month 10.
Description of risks
Serious risks or undesired effects of questionnaires have
not been described in the literature. No specific risk for
participating patients can be stated. The management of
the patients remains in the responsibility of the treating
physician.
Ethical and legal aspects
Ethical principles
The study is being conducted in accordance with medical
professional codex and the Helsinki Declaration, i.e. the
ICH Guideline for Good Clinical Practice (GCP) E6 of
1996, the CPMP/ICH/135/95 of September 1997 and its
amendments [39-41]. The study is also in accordance with
the German Federal Data Security Law (BDSG). All profes-
sionals participating at the study oblige themselves to
adhere to the abovementioned declaration and law.
Study participation of patients is voluntary and can be
cancelled at any time without provision of reasons and
without negative consequences for their future medical
care.
Patient informed consent
Previous to study participation patients receive written
and spoken information about the content and extent of
the planned study; for instance about potential benefits
for their health and potential risks. In case of acceptance
they sign the informed consent form. In case of study dis-
continuation all material will be destroyed or the patient
will be asked if he/she accepts that existing material can be
analysed in the study.
Legal principles
Vote of the ethics committee
The study protocol was approved by the ethics committee
of the University of Heidelberg previous to the start of the
study in November 2006. Inclusion of patients/partici-
pants did not start unless there was a written and unre-
stricted positive vote of the ethics committee (approval
number 303/2006). The study protocol was also
approved by the ethics committee of the medical associa-
tion of the state of Baden-Württemberg (approval number
B-244-06-f). Both votes were received in October 2006.
The study is registered (ISRCTN30822978).
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to German Federal Data Security Law (BDSG).
The patient questionnaires and original CRFs are collected
by the study nurse and mailed to the KKSL. These study
related data and documents are stored on a protected cen-
tral server of the KKSL. Only direct members of the inter-
nal study team can access the respective files.
Intermediate and final reports as well as the documenta-
tion of the Case management are stored in the office of the
Department of General Practice and Health Services
Research at the University Hospital Heidelberg.
The press copies of the clinical data and the documenta-
tion of the case management are stored in the centres for
at least 10 years.
Discussion
As the targeted patient group is mostly cared for and
treated by GPs, a comprehensive primary care-based
guideline implementation including somatic, psychoso-
matic and organisational aspects of the delivery of care
(HICMAn) is a promising intervention applying proven
strategies for optimal care of patients with CHF.
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